Friday, Nov. 7, 8:00 a.m.
How I Built This: Unique Clinical Programs to Improve CHD Care
This session will explore programmatic advances in fields impacting pediatric and adult congenital cardiovascular science, focusing on a lifespan approach to various areas impacting patients with CHD. Experts from diverse subspecialties will discuss the latest in programmatic developments in exercise rehabilitation, acute care cardiology, CV quality improvement, young adult single ventricle surveillance, CV transition medicine, preventative cardiology, and cardiovascular genetics. The session will include engaging talks to foster cross-disciplinary collaboration and knowledge sharing.

Friday, Nov. 7, 9:45 a.m.
What A Busy Cardiologist Needs to Know About Genetics
This session will address practical issues in genetic testing and therapy for cardiovascular diseases, including exercise safety, communicating the results of genetic tests for sudden cardiac death, and the role of pharmacogenomics. Experts will discuss the risks of genetic testing, the potential of gene therapy, and how to manage variants of uncertain significance (VUS).

Friday, Nov. 7, 12:30 p.m.
Keep it Simple: Cutting Edge Vascular, Lipid, and Coagulation Research
This session is innovative talks covering a broad range of hot topics in atherosclerosis, thrombosis, vascular biology, and lipoprotein metabolism. This will be a great forum for both researchers and clinicians to learn about important new research in bite-sized and to-the-point presentations.

Friday, Nov. 7, 2:15 p.m.
Implementing Protocolized Patient Care Structures: Instead of Relying on Everyone Being Above Average - An Innovation Session
Patient care structures, when designed effectively, can be highly valuable as they can significantly improve patient experience, quality of care, and overall healthcare outcomes by facilitating better coordination, and communication. This session will introduce high impact patient care structures that improve outcomes in patients with heart disease.

Friday, Nov. 7, 4:00 p.m.
Innovations in Pediatric Cardiovascular Science: Pioneering Pathways for the Future
This session will explore groundbreaking advances in pediatric cardiovascular science, focusing on innovative therapies, technological advancements, and equitable care practices. Experts from diverse subspecialties will discuss emerging trends in ventricular assist devices (VADs), transplantation innovations, artificial intelligence in cardiovascular diagnostics, and solutions to address disparities in pediatric heart care. The session will include engaging talks and a panel discussion to foster cross-disciplinary collaboration and knowledge sharing.

Saturday, Nov. 8, 9:45 a.m.
Forgotten No More: The Current Belle of the Ball? Breakthrough Evolutions in Hypertrophic Cardiomyopathy
This session will be the inaugural collaborative session between the AHA and HCM Society. It will feature cross-disciplinary faculty from basic science, genetics, heart failure, imaging and surgery, highlighting the latest updates in new therapies for HCM.

Saturday, Nov. 8, 9:45 a.m.
2025-2035: Questions to be Addressed in Heart Failure Research in the Next 10 Years
Research in heart failure over the next decade will address critical questions such as the mechanisms underlying disease progression, personalized treatment strategies, and the role of emerging technologies. Understanding these aspects aims to improve patient outcomes, develop innovative therapies, and enhance quality of life for those with heart failure. This session will shed light on basic cardiovascular research aspects, offering engaging and thought-provoking presentations.

Saturday, Nov. 8, 1:30 a.m.
Shifting Paradigms in Lipid Management for ASCVD Risk
This session combines talks with a case presentation regarding a patient with mixed hyperlipidemia, elevated lipoprotein(a) and ASCVD. The panel discussion will touch upon elements of the case and address questions from the moderators and the audience.

Saturday, Nov. 8, 3:15 a.m.
Meet and Greet: The 2025 Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults
This main event will unveil the newly released 2025 AHA/ACC guideline for the prevention, detection, evaluation and treatment of high blood pressure in adults. Guideline leaders will provide an overview of the guideline with a focus on new recommendations and those that differ from prior guidelines. The session will cover the general approach to evaluation and treatment of high blood pressure, then highlight specific recommendations for subgroups related to comorbidities. Practical strategies to promote implementation are key to making meaningful changes and will be discussed by seasoned experts in the field.

Sunday, Nov. 9, 8:00 a.m.
The Future of Kidney Care: Bioartificial Organs, AI, and Breakthrough Therapies
These talks cover groundbreaking advancements in healthcare, particularly in kidney and heart disease management. They highlight innovations like the bioartificial kidney, emerging technologies in heart failure and chronic kidney disease (CKD) treatment, the latest research into the molecular causes of CKD, and the role of artificial intelligence in improving early detection and prediction of CKD risk.

Sunday, Nov. 9, 8:00 a.m.
The New 2025 Guideline for Acute Coronary Syndromes
This session will be a must-attend event for anyone interested in learning and understanding the new AHA/ACC Guideline for Acute Coronary Syndromes. Beyond highlighting the most important things to know from the new guideline, the session will take attendees behind the scenes to understand how the writing group found consensus on the most controversial topics. An expert panel will include lead authors from past AHA/ACC guidelines and recent ESC guidelines for critical commentary. Finally, the session will provide attendees with practical applications of the new guidelines to curated challenging cases.

Sunday, Nov. 9, 9:45 a.m.
Pregnancy-Related Hypertensive Disorders and Brain Health
This session explores the intersection of pregnancy-related hypertensive disorders (such as preeclampsia) and their profound impact on brain health. Experts will delve into how these conditions, which affect both maternal cardiovascular and neurological systems, can lead to long-term cognitive issues and neurological complications. The session will cover the pathophysiology of pregnancy-induced hypertension, the risks for stroke and cognitive decline, and how these conditions can be managed to protect both maternal and fetal health. Join leading neurologists and cardiologists as they provide insights on preventing, diagnosing, and treating pregnancy-related hypertensive disorders for better long-term health outcomes.

Sunday, Nov. 9, 9:45 a.m.
Nobel Laureate Address
Ardem Patapoutian was jointly awarded the 2021 Nobel Prize in Physiology or Medicine for his collaborative work that discovered the mechanism that converts how temperature and mechanical stimuli, such as pressure and cell stretching, are converted into electrical impulses that are then perceived by the central nervous system. Ardem Patapoutian used pressure-sensitive cells to discover a novel class of sensors called PIEZO channels that respond to mechanical stimuli such as cell stretching and pressure. Thanks to this pioneering work, we now understand that PIEZO ion channels exist in the cell membrane and function as key transducers for converting mechanical stimuli into electrochemical signals. Furthermore, PIEZO channels are expressed in cardiomyocytes and vascular cells, and convert mechanical forces like blood pressure, intracardiac pressures, and shear stress into electrical signals, thus regulating a range of cardiovascular functions such as vascular tone, blood pressure.

Sunday, Nov. 9, 3:30 p.m.
Adding Years to Life and Life to Years
As the population ages, cardiovascular interventions must evolve to address the unique physiologic, functional, and cognitive challenges in older adults. This session will explore how biological aging impacts procedural decision-making in coronary, structural, vascular, and electrophysiologic interventions. Experts will discuss frailty assessment, patient selection, risk mitigation, shared decision-making, and emerging innovations aimed at improving outcomes in older adults undergoing cardiovascular interventions.

Sunday, Nov. 9, 3:30 p.m.
Cardiovascular Disease Prevention Extends Beyond the Heart
This session will explore unique angles to cardiovascular disease prevention. Historically, preventive therapies targeted cardiovascular disease complications. Emerging evidence suggests that the impact of cardiovascular disease prevention efforts extends beyond the heart and vasculature to systemic effects. Specifically, evolving approaches to cardiovascular disease prevention likely have beneficial effects on oncologic, kidney, liver, brain, and musculoskeletal systems. The emerging evidence in this space will be discussed here.

Monday, Nov. 10, 8:00 a.m.
Innovation at the Bench to Prime-Time Therapies at the Bedside
This innovation session will feature how developments in basic science have resulted in a number of new cellular/molecular-based therapeutics that are being applied to the bedside.

Monday, Nov. 10, 8:00 a.m.
Smarter Care, Healthier Hearts: AI’s Role in the Future of Cardiovascular Medicine
Artificial intelligence is poised to transform cardiovascular care, but its impact depends on health systems being ready to adopt, integrate, and scale these innovations. This session explores the critical steps needed for real-world AI implementation, from automating quality measurement to leveraging multimodal and consumer-driven technologies. Experts will discuss how to navigate challenges, ensure equitable access, and harness AI’s full potential to drive smarter care and better outcomes in cardiovascular medicine.

Monday, Nov. 10, 9:45 a.m.
Innovations in Valvular Heart Disease: Talks from Basic Science to Clinical Trials to Breakthrough Innovations in Surgical and Transcatheter Therapies
This session highlights groundbreaking advancements shaping the future of aortic stenosis and valvular heart disease diagnosis and treatment. Experts will discuss the Detect AS Trial, which leverages electronic provider notifications to enhance the recognition and management of severe aortic stenosis. The transformative role of artificial intelligence in AS diagnosis will be explored, showcasing how cutting-edge technology is already revolutionizing clinical practice. Attendees will gain insights into basic science breakthroughs driving innovation in valvular heart disease and how these discoveries translate into bedside treatment. Looking ahead, the session will explore the next generation of transcatheter innovations and robotic surgical advancements poised to redefine valvular interventions. This comprehensive discussion will provide a forward-looking perspective on the most promising scientific and technological advances in valvular heart disease.

Monday, Nov. 10, 9:45 a.m.
Don't risk it: AF related stroke prevention
Seems like AF is showing up everywhere we look these days, while AI is the solution to all ails. But how do we manage all the generated data and use it to actually impact outcomes? How might AF management and stroke prevention be further advancing with novel imaging strategies, new left atrial appendage occlusion technologies, and a better understanding of stroke risk after AF ablation?

Monday, Nov. 10, 1:30 p.m.
Leveraging Artificial Intelligence in Cardiac Imaging
Advances in artificial intelligence (AI) based strategies have led to rapid increase in the use of these tools in everyday clinical practice. Multimodality imagers are faced with growing challenges in the best and optimal uses of these tools in the acquisition and interpretation of clinical cardiovascular imaging. Given the rapidly evolving nature of the clinical applications of the tools, the session seeks to simplify these tools to allow the best uptake into care.

Monday, Nov. 10, 1:30 p.m.
HFpEF in 2025: Trials and Triumphs
Approximately 32 million people worldwide have heart failure with preserved (HFpEF) or mildly reduced ejection fraction. HFpEF is becoming the predominant form of heart failure and represents the largest unmet need in the field. After decades without effective therapies, treatments for HFpEF are now becoming available. Recently, clinical trials have shown three positive results for novel therapies, leading to three new FDA submissions. This must-attend session will provide updates on HFpEF in 2025, spanning basic, clinical, and population health domains.

Monday, Nov. 10, 3:15 p.m.
Cardiovascular Precision Therapy is at the Bedside
More than a decade of genetics and genomics has fueled the discovery of novel therapies aimed at the underlying causes of disease across the spectrum of cardiovascular morbidity. This session will introduce the novel technologies coming to clinical trials and commerical market for common and rare diseases, address the nuances of patient selection for these drugs, and discuss the clinical infrastructure needed to ensure patient safety as we forge ahead to a new era of precision therapeutics.